SGHT

Sight Sciences, Inc. (SGHT) | Rumor.io

Sight Sciences

SGHT

Attention (50-day avg)0%

Attention rank (50-day avg)#4,437

Bullish sentiment (50-day avg)100%

Price to earnings ratio-12.5

Market capitalization510.7M

Earnings per share-0.55

Dividend yield (TTM)—

Revenue (annual)77.4M

Net income (annual)-38.4M

Social

What share of all stock conversation is about SGHT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% +0

Mar 30

The US District Court has preserved the jury's verdict of willful infringement by Alcon against Sight Sciences, awarding over $34M in past damages and ongoing royalties through 2028.
The court's order is a significant legal victory for Sight Sciences, potentially impacting the company's stock and sector rotation.
The verdict is expected to have a positive impact on Sight Sciences, with potential momentum shift and options flow to watch for.

Generated by AI

Sentiment

Of the messages about SGHT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% 0	100% +3.45
Bearish	0%	0%	0% 0	0% -3.45

Oct 18

$SGHT has the potential for a +35% breakout due to strong momentum and continuation potential following international expansion news.
The stock has shown a perfect storm brewing, with a +35% breakout confirming its strong momentum and continuation potential.
A key level to watch for $SGHT is $4.20, as holding above this level could be a positive sign for the stock's future performance.

Generated by AI

Topics

Of the messages about SGHT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	0%	25.43%
Technical Analysis	100%	100%	100%	12.14%
Macro	0%	0%	0%	0.58%
Earnings	0%	0%	0%	1.73%
Analysts	0%	0%	0%	60.12%
Controversies	0%	0%	0%	0%

Community

Of the messages about SGHT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	5.52%
Newcomers	100%	100%	100%	94.48%

Oct 17

The company has secured Medicare pricing for its TearCare interventional dry eye procedure, which may improve patient access and reimbursement.
Sight Sciences has announced a fee schedule establishment from two key Medicare Administrative Contractors, Novitas Solutions and First Coast Service Options, covering 10.4 million estimated covered lives.
The company has raised its full-year guidance to $72-$76 million and has $101 million in cash on hand, providing a solid runway for future growth.

Generated by AI

MENLO PARK, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference in New York, NY. Sight Sciences’ management is scheduled to present on Tuesday, September 15, 2026, at 6:15 am

28d agoYahoo Finance Singapore

Sight Sciences (SGHT) Q2 2026 Earnings Call Transcript

Detailed price information for Sight Sciences Inc (SGHT-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Sight Sciences Appoints New Chief Legal Officer Rashid

Detailed price information for Sight Sciences Inc (SGHT-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down

1mo agoInvesting.com

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Sight Sciences (SGHT)

Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about SGHT also mention

#	Name	Attention
1	OSR Health, Inc.OSRH	0.01%+0
2	Alpha Technology Group Limited Class A Ordinary SharesATGL	0%0
3	MOFG - MidWestOne Financial Group, Inc.	——
4	CREV - Carbon Revolution Public Limited Ordinary Shares	——
5	Solidion Technology Inc.STI	0%new
6	NextCure, Inc.NXTC	0%0
7	Sezzle Inc.SEZL	0%+0
8	H&R Block Inc.HRB	0%+0
9	Estrella Immunopharma, Inc.ESLA	0%0
10	Genenta Science S.p.A. Sponsored ADRGNTA	0%0

Sight Sciences, Inc.

Healthcare
Medical Devices

Sight Sciences, Inc. is an ophthalmic medical device company focused on developing and commercializing interventional technologies for glaucoma and dry eye disease. Its current product portfolio includes the OMNI Surgical System family for minimally invasive glaucoma procedures, the SION Surgical Instrument for trabecular meshwork excision, and the TearCare System for treating evaporative dry eye associated with meibomian gland dysfunction. The company serves eyecare providers, including ophthalmologists and optometrists, by offering tools designed to address key causes of intraocular pressure buildup and tear-film dysfunction. Sight Sciences operates through its Surgical Glaucoma and Dry Eye segments, positioning its products across procedural eyecare settings where device-based treatment options are used to support patient care. Headquartered in Menlo Park, California, Sight Sciences plays a focused role in the medical technology market by supplying specialized devices for prevalent eye conditions.

Website

Location

4040 Campbell Avenue

Menlo Park, CA, 94025

United States

Social

What share of all stock conversation is about SGHT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% +0

Mar 30

The US District Court has preserved the jury's verdict of willful infringement by Alcon against Sight Sciences, awarding over $34M in past damages and ongoing royalties through 2028.
The court's order is a significant legal victory for Sight Sciences, potentially impacting the company's stock and sector rotation.
The verdict is expected to have a positive impact on Sight Sciences, with potential momentum shift and options flow to watch for.

Generated by AI

Sentiment

Of the messages about SGHT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% 0	100% +3.45
Bearish	0%	0%	0% 0	0% -3.45

Oct 18

$SGHT has the potential for a +35% breakout due to strong momentum and continuation potential following international expansion news.
The stock has shown a perfect storm brewing, with a +35% breakout confirming its strong momentum and continuation potential.
A key level to watch for $SGHT is $4.20, as holding above this level could be a positive sign for the stock's future performance.

Generated by AI

Topics

Of the messages about SGHT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	0%	25.43%
Technical Analysis	100%	100%	100%	12.14%
Macro	0%	0%	0%	0.58%
Earnings	0%	0%	0%	1.73%
Analysts	0%	0%	0%	60.12%
Controversies	0%	0%	0%	0%

Community

Of the messages about SGHT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	5.52%
Newcomers	100%	100%	100%	94.48%

Oct 17

The company has secured Medicare pricing for its TearCare interventional dry eye procedure, which may improve patient access and reimbursement.
Sight Sciences has announced a fee schedule establishment from two key Medicare Administrative Contractors, Novitas Solutions and First Coast Service Options, covering 10.4 million estimated covered lives.
The company has raised its full-year guidance to $72-$76 million and has $101 million in cash on hand, providing a solid runway for future growth.

Generated by AI

Sight Sciences

Social

Mar 30

Sentiment

Oct 18

Topics

Community

Oct 17

News

Sight Sciences at Morgan Stanley conference: growth returns across two platforms

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15

Sight Sciences (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences Appoints New Chief Legal Officer Rashid

Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Sight Sciences (SGHT)

Also Discussed

Sight Sciences, Inc.

Company Information

Location

News

Sight Sciences at Morgan Stanley conference: growth returns across two platforms

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15

Sight Sciences (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences Appoints New Chief Legal Officer Rashid

Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Sight Sciences (SGHT)

Also Discussed

Social

Mar 30

Sentiment

Oct 18

Topics

Community

Oct 17